MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
